Clicky

Pharming Group NV(PHARM)

Description: Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.


Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Molecular Biology Rare Diseases Gene Therapy Genetic Engineering Hereditary Angioedema Angioedema Acute Kidney Injury Complement Deficiency Pharming Treatment Of Rare Diseases C1 Inhibitor Fabry Diseases Acute Hereditary Angioedema Ruconest

Home Page: www.pharming.com

Darwinweg 24
Leiden, 2333 CR
Netherlands
Phone: 31 71 524 7400


Officers

Name Title
Dr. Sijmen de Vries M.B.A., M.D., MBA Pres, CEO & Exec. Director
Dr. Bruno M. L. Giannetti Consultant
Mr. Jeroen Wakkerman Chief Financial Officer
Ms. Mireille Sanders M.Sc. Chief Operations Officer
Susanne Embleton Investor Relations Mang.
Mr. Ruud Van Outersterp Chief Ethics & Compliance Officer
Mr. Anurag Relan Chief Medical Officer
Mr. Stephen Toor Chief Commercial Officer & GM of Americas

Exchange: AS

Country: NL : Netherlands

Currency: Euro (€)

Forward PE: 149.2537
Trailing PE: 28.55
Price-to-Book MRQ: 3.8487
Price-to-Sales TTM: 3.5691
IPO Date:
Fiscal Year End: December
Full Time Employees: 277
Back to stocks